Back to Search
Start Over
Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
- Source :
-
Vaccine [Vaccine] 2024 Sep 17; Vol. 42 (22), pp. 126010. Date of Electronic Publication: 2024 May 27. - Publication Year :
- 2024
-
Abstract
- JN.1, the dominating SARS-CoV-2 variant, is antigenically distinct from ancestral BA.1, BA.5 and XBB.1.5 variants, raising concern about effectiveness of updated COVID-19 vaccines. Here, we compared the neutralizing antibody response against JN.1, 1-month after receipt of the three available Moderna mRNA vaccines. Sera obtained from 37, 30 and 30 XBB.1.5, BA.1 and BA.4-5 -vaccine recipients, respectively, were tested for anti-RBD IgG and for JN-1 specific neutralizing antibody levels. Geometric mean fold rise (GMFR) in JN.1 specific neutralizing titers was 27 (95 % CI: 17-43.1), 10.1 (95 % CI: 6.48-15.7) and 8.77 (95 % CI: 5.69-13.5) following XBB.1.5, BA.1 and BA.4-5 vaccines, respectively, translating into a 64 % lower adjusted response (geometric mean ratio [GMR] = 0.36, 95 % CI: 0.21-0.6) in the BA.1 arm, and a 75 % lower response (GMR = 0.25, 95 % CI: 0.15-0.43) in the BA.4-5 arm. This suggests that XBB.1.5 vaccination will most likely, result in improved effectiveness against JN.1 compared with other COVID-19 vaccines.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Spyros Chalkias, Rituparna Das and Gamal Elfatarany are employees of Moderna, Inc. and may hold stock/stock options in the company. Gili Regev-Yochay served as a consultant to Merck, GSK, Astrazenca, Pfizer and Moderna.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Subjects :
- Humans
Female
Male
Middle Aged
Adult
mRNA Vaccines immunology
Immunoglobulin G blood
Immunoglobulin G immunology
Spike Glycoprotein, Coronavirus immunology
Spike Glycoprotein, Coronavirus genetics
Aged
Vaccines, Synthetic immunology
Vaccines, Synthetic administration & dosage
Immunogenicity, Vaccine
Antibodies, Neutralizing blood
Antibodies, Neutralizing immunology
COVID-19 Vaccines immunology
COVID-19 Vaccines administration & dosage
Antibodies, Viral blood
Antibodies, Viral immunology
COVID-19 prevention & control
COVID-19 immunology
SARS-CoV-2 immunology
SARS-CoV-2 genetics
Immunity, Humoral
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2518
- Volume :
- 42
- Issue :
- 22
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 38806352
- Full Text :
- https://doi.org/10.1016/j.vaccine.2024.05.058